CN109295082B - 肿瘤特异性基因表达盒、重组表达载体及构建方法和应用 - Google Patents
肿瘤特异性基因表达盒、重组表达载体及构建方法和应用 Download PDFInfo
- Publication number
- CN109295082B CN109295082B CN201811173301.9A CN201811173301A CN109295082B CN 109295082 B CN109295082 B CN 109295082B CN 201811173301 A CN201811173301 A CN 201811173301A CN 109295082 B CN109295082 B CN 109295082B
- Authority
- CN
- China
- Prior art keywords
- gene
- suicide
- expression vector
- tumor
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013604 expression vector Substances 0.000 title claims abstract description 47
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 42
- 230000014509 gene expression Effects 0.000 title claims abstract description 37
- 238000003259 recombinant expression Methods 0.000 title claims abstract description 36
- 238000010276 construction Methods 0.000 title abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 96
- 108010075254 C-Peptide Proteins 0.000 claims abstract description 17
- 101150074355 GS gene Proteins 0.000 claims abstract description 16
- 230000004069 differentiation Effects 0.000 claims abstract description 14
- 108010080611 Cytosine Deaminase Proteins 0.000 claims abstract description 13
- 241000700584 Simplexvirus Species 0.000 claims abstract description 13
- 108020004440 Thymidine kinase Proteins 0.000 claims abstract description 13
- 201000001441 melanoma Diseases 0.000 claims abstract description 13
- 108700026220 vif Genes Proteins 0.000 claims abstract description 12
- 239000013598 vector Substances 0.000 claims description 18
- 239000003550 marker Substances 0.000 claims description 10
- 239000013603 viral vector Substances 0.000 claims description 7
- 238000001976 enzyme digestion Methods 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 108090000237 interleukin-24 Proteins 0.000 abstract description 20
- 102000003898 interleukin-24 Human genes 0.000 abstract description 19
- 230000000259 anti-tumor effect Effects 0.000 abstract description 10
- 230000004927 fusion Effects 0.000 abstract description 5
- 206010010144 Completed suicide Diseases 0.000 abstract description 3
- 230000002103 transcriptional effect Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 21
- 210000004881 tumor cell Anatomy 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 230000000981 bystander Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 230000005758 transcription activity Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000000311 Cytosine Deaminase Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 102200157658 rs1555229948 Human genes 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811173301.9A CN109295082B (zh) | 2018-10-09 | 2018-10-09 | 肿瘤特异性基因表达盒、重组表达载体及构建方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811173301.9A CN109295082B (zh) | 2018-10-09 | 2018-10-09 | 肿瘤特异性基因表达盒、重组表达载体及构建方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109295082A CN109295082A (zh) | 2019-02-01 |
CN109295082B true CN109295082B (zh) | 2021-06-15 |
Family
ID=65161844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811173301.9A Active CN109295082B (zh) | 2018-10-09 | 2018-10-09 | 肿瘤特异性基因表达盒、重组表达载体及构建方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109295082B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1528887A (zh) * | 2003-10-15 | 2004-09-15 | 中国科学院上海生命科学研究院 | 肿瘤靶向双基因-病毒的构建方法 |
CN101760475A (zh) * | 2008-12-25 | 2010-06-30 | 中国科学院生物物理研究所 | 重组逆转录病毒载体 |
CN101812448A (zh) * | 2010-01-15 | 2010-08-25 | 浙江大学 | 一种肝癌靶向双重组凋亡蛋白表达序列及应用 |
CN102344933A (zh) * | 2010-05-21 | 2012-02-08 | 圣太科医疗科技(上海)有限公司 | 靶向人肝癌细胞含有抑癌基因的真核表达载体质粒 |
CN104762323A (zh) * | 2014-01-08 | 2015-07-08 | 张雅洁 | 高效包装与表达黑色素瘤分化相关基因-7的腺病毒构建方法 |
CN105734080A (zh) * | 2016-01-30 | 2016-07-06 | 山西大学 | 一种靶向抗癌基因-质粒及其构建方法和应用 |
-
2018
- 2018-10-09 CN CN201811173301.9A patent/CN109295082B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1528887A (zh) * | 2003-10-15 | 2004-09-15 | 中国科学院上海生命科学研究院 | 肿瘤靶向双基因-病毒的构建方法 |
CN101760475A (zh) * | 2008-12-25 | 2010-06-30 | 中国科学院生物物理研究所 | 重组逆转录病毒载体 |
CN101812448A (zh) * | 2010-01-15 | 2010-08-25 | 浙江大学 | 一种肝癌靶向双重组凋亡蛋白表达序列及应用 |
CN102344933A (zh) * | 2010-05-21 | 2012-02-08 | 圣太科医疗科技(上海)有限公司 | 靶向人肝癌细胞含有抑癌基因的真核表达载体质粒 |
CN104762323A (zh) * | 2014-01-08 | 2015-07-08 | 张雅洁 | 高效包装与表达黑色素瘤分化相关基因-7的腺病毒构建方法 |
CN105734080A (zh) * | 2016-01-30 | 2016-07-06 | 山西大学 | 一种靶向抗癌基因-质粒及其构建方法和应用 |
Non-Patent Citations (4)
Title |
---|
HSV-TK/CD基因联合IL-2基因体内治疗肝癌;黄嘉凌 等;《肿瘤》;20040925;第24卷(第5期);467-469 * |
Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines;Sakkas A et al;《J Cancer》;20141231;第5卷(第5期);368-377 * |
不同接头的白蛋白干扰素在毕赤酵母中表达的研究;刘磊 等;《生物学杂志》;20120418;第29卷(第2期);100-102 * |
靶向治疗肺癌双自杀基因HSV-TK/CD真核表达载体的构建;李富骊 等;《中国癌症杂志》;20070130;第17卷(第1期);37-40 * |
Also Published As
Publication number | Publication date |
---|---|
CN109295082A (zh) | 2019-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7216877B2 (ja) | 新規なCRISPR/Cas12f酵素およびシステム | |
CN107513531B (zh) | 用于内源性过表达lncRNA-XIST的gRNA靶点序列及其应用 | |
AU2015299850B2 (en) | Genome editing using Campylobacter jejuni CRISPR/CAS system-derived RGEN | |
Lewandowska | The missing puzzle piece: splicing mutations | |
TW202043249A (zh) | 編輯rna的方法和組合物 | |
CN111770992A (zh) | CRISPR-Cas12j酶和系统 | |
CA3012607A1 (en) | Crispr enzymes and systems | |
CN111378686B (zh) | 一种高效形成环状RNA的过表达载体pCircleVG及其构建方法 | |
CN112020560A (zh) | 一种RNA编辑的CRISPR/Cas效应蛋白及系统 | |
CN112105728A (zh) | CRISPR/Cas效应蛋白及系统 | |
US20230279389A1 (en) | Recombinant nucleic acid molecule and application thereof in preparation of circular rna | |
CN113015798A (zh) | CRISPR-Cas12a酶和系统 | |
US10711046B2 (en) | Method for establishing eukaryotic expression cell line of CD36 mutant gene that encodes CD36 deficiency | |
CN107245493B (zh) | 一种表达受茶碱调控的适体核酶修饰型sgRNA的载体及应用 | |
CN114574483A (zh) | 基于翻译起始元件点突变的重组核酸分子及其在制备环状rna中的应用 | |
WO2022167009A1 (zh) | 靶向Aqp1 mRNA的sgRNA及其载体与应用 | |
CN109295082B (zh) | 肿瘤特异性基因表达盒、重组表达载体及构建方法和应用 | |
CN109295102B (zh) | 肿瘤特异性基因表达盒、重组表达载体及构建方法和应用 | |
CN110499335B (zh) | CRISPR/SauriCas9基因编辑系统及其应用 | |
CN110551762B (zh) | CRISPR/ShaCas9基因编辑系统及其应用 | |
Dormiani et al. | Long-term and efficient expression of human β-globin gene in a hematopoietic cell line using a new site-specific integrating non-viral system | |
CN114990093B (zh) | 氨基酸序列小的蛋白序列mini rfx-cas13d | |
CN113930411A (zh) | 新型CRISPR-Cas12M酶和系统 | |
Lin et al. | Gene therapy for human ovarian cancer cells using efficient expression of Fas gene combined with γδT cells | |
Huang et al. | Transcription of the rat testis-specific Rtdpoz-T1 and-T2 retrogenes during embryo development: co-transcription and frequent exonisation of transposable element sequences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240718 Address after: No. E4-25 Zhongguancun Science and Technology City, No.1 Northwest Sixth Road, Zhangdian District, Zibo City, Shandong Province, China 255000 Patentee after: Zibo wisdom Intellectual Property Service Co.,Ltd. Country or region after: China Address before: No. 601, Jinsui Avenue, Hongqi District, Xinxiang City, Henan Province 453099 Patentee before: XINXIANG MEDICAL University Country or region before: China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240719 Address after: No. 158, Shangtang Road, Xiacheng District, Hangzhou, Zhejiang Province Patentee after: Gan Yichao Country or region after: China Patentee after: Shao Ruifeng Address before: No. E4-25 Zhongguancun Science and Technology City, No.1 Northwest Sixth Road, Zhangdian District, Zibo City, Shandong Province, China 255000 Patentee before: Zibo wisdom Intellectual Property Service Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |